Ching-Lung Lo

Ching-Lung Lo

Auto-generated profile, based on publicly available information

Ching-Lung Lo

Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Center for Infection Control, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
CSCheng Len Sy
Cheng Len Sy
PCPao-Yu Chen
Pao-Yu Chen
CCChun-Wen Cheng
Chun-Wen Cheng
LHLing-Ju Huang
Ling-Ju Huang
CWChing-Hsun Wang
Ching-Hsun Wang
FWFu-Der Wang
Fu-Der Wang
Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, prolonged hospital stays and increased mortality. Infection rates due to multidrug-resistant organisms (MDRO) are increasing globally. Active agents against MDRO are limited despite an increased in the availability of novel antibiotics in recent years. This guideline aims to assist clinicians in the management of infections due to MDRO. The 2019 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group, comprising of infectious disease specialists from 14 medical centers in Taiwan, reviewed current evidences and drafted recommendations for the treatment of infections due to MDRO. A nationwide expert panel reviewed the recommendations during a consensus meeting in Aug 2020, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes recommendations for selecting antimicrobial therapy for infections caused by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales, and vancomycin-resistant Enterococcus. The guideline takes into consideration the local epidemiology, and includes antimicrobial agents that may not yet be available in Taiwan. It is intended to serve as a clinical guide and not to supersede the clinical judgment of physicians in the management of individual patients.

1 June 2017 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
CLChing-Lung Lo
Ching-Lung Lo
CLChing-Chi Lee
Ching-Chi Lee
CLChia-Wen Li
Chia-Wen Li
MLMing-Chi Li
Ming-Chi Li
PHPo-Ren Hsueh
Po-Ren Hsueh
WKWen-Chien Ko
Wen-Chien Ko
For extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae infections, carbapenems are recommended as first line therapy, and clinical data on the therapeutic efficacy of fluoroquinolones (FQs) is limited. This study compares the efficacy of FQs and carbapenems for bloodstream infections caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae. Between 2008 and 2010, adults with ESBL-producing E. coli or K. pneumoniae bacteremia at two medical centers were reviewed. Adults receiving definitive FQ or carbapenem therapy were compared in a propensity score-matched analysis, and 30-day mortality was the primary endpoint. A total of 299 patients were eligible. Patients receiving a FQ (n = 24), either ciprofloxacin or levofloxacin, had a lower 30-day mortality rate than those with carbapenem therapy (8.3%, 2/24 vs. 23.3%, 64/275; p = 0.12). Multivariate regression analysis revealed that a critical illness [Pitt bacteremia score ≥ 4 points; odds ratio (OR), 7.09; p < 0.001], rapidly fatal underlying disease (OR, 5.73; p < 0.001), and hospital-associated infection (OR, 2.57; p = 0.01) were independently associated with 30-day mortality. By contrast, FQ definitive therapy was a protective factor compared with carbapenems (OR, 0.18; p = 0.04). There were 72 matched cases with carbapenem therapy in a propensity score-matched analysis, and a difference in the 30-day mortality rate of two groups was noted (8.3% vs. 29.2%; p = 0.05). For ESBL-producing E. coli or K. pneumoniae bacteremia, ciprofloxacin or levofloxacin, if active in vitro, can be considered as a carbapenem-sparing alternative.

1 February 2021 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
NLNan-Yao Lee
Nan-Yao Lee
CLChing-Lung Lo
Ching-Lung Lo
PCPo-Lin Chen
Po-Lin Chen
LSLing-Shan Syue
Ling-Shan Syue
CLChia-Wen Li
Chia-Wen Li
WKWen-Chien Ko
Wen-Chien Ko

30 May 2024 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
TYTian-Yu You
Tian-Yu You
CLChing-Lung Lo
Ching-Lung Lo
WTWen-Chia Tsai
Wen-Chia Tsai
HJHAOEN JAN
HAOEN JAN
WKWen-Chien Ko
Wen-Chien Ko
NLNan-Yao Lee
Nan-Yao Lee
As limited antibiotic options are available for the treatment of carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSIs), the optimal treatment duration for CRKP BSIs is unclear. Our objective was to investigate whether short courses (6-10 days) are as effective as prolonged courses (≥11 days) of active antibiotic therapy for CRKP BSIs. A retrospective cohort study comprising adults with monomicrobial CRKP BSI receiving a short or prolonged course of in vitro active therapy at a medical center was conducted between 2010 and 2021. Comparisons of two therapeutic strategies were assessed by the logistic regression model and propensity score analysis. The primary endpoint was 30-day crude mortality. Secondary outcomes included recurrent BSIs, the emergence of multidrug-resistant organisms and candidemia during hospitalization after completing antibiotic therapy for CRKP BSIs. Of 263 eligible adults, 160 (60.8%) were male, and the median (interquartile range) age was 69.0 (53.0-76.0) years. Common comorbidities included diabetes (143 patients, 54.4%), malignancy (75, 28.5%), cerebrovascular accident (58, 22.1%), and hemodialysis (49, 18.6%). The 30-day mortality rate was 8.4% (22 patients). Of 84 propensity score well-balanced matched pairs, the 30-day mortality was similar in the short-course and prolonged-course group (6.0% and 7.1%, respectively; P = 1.00). However, there were less episodes candidemia in the short-course group (1.2% versus 13.1%; odds ratio, 0.08; 95% confidence interval, 0.01-0.63; P = 0.005). Short courses of active therapy for CRKP BSIs demonstrate comparable clinical outcomes to prolonged courses and are associated with a lower risk of subsequent candidemia.

15 July 2025 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
SYSheng-Jie Yeh
Sheng-Jie Yeh
CLChia-Wen Li
Chia-Wen Li
CLChing-Lung Lo
Ching-Lung Lo
PCPo-Lin Chen
Po-Lin Chen
BHBo-Ming Huang
Bo-Ming Huang
NLNan-Yao Lee
Nan-Yao Lee
As the population of people living with HIV (PLWH) ages, the burden of non-cardiometabolic diseases-including diabetes mellitus (DM), hypertension, and hyperlipidemia-has increased. However, data on age-specific cardiometabolic multimorbidity and real-world treatment gaps remain limited. We conducted a retrospective study of 227 PLWH aged ≥50 years at a tertiary HIV center in Taiwan, stratified into premature-old (50-64 years) and old (≥65 years) groups. We assessed prevalence, incidence, and risk factors of cardiometabolic conditions, and applied Taiwan National Health Insurance(TNHI) criteria to evaluate statin eligibility. Among 227 PLWH, 182 were aged 50-64 (premature-old) and 45 were ≥65 (old). At follow-up, the prevalence of diabetes, hypertension, and hyperlipidemia reached 32.2 %, 48.5 %, and 76.2 %, respectively. Multimorbidity increased from 28.0 % to 46.7 % in premature-old group and 48.9 %-73.3 % in old group. Risk factors for DM included body mass index (BMI) ≥24.0 kg/m2 and high-density lipoprotein cholesterol (HDL-C) 5 years, BMI ≥24.0 kg/m2, HDL-C <40 mg/dL, chronic kidney disease (CKD), and specific antiretroviral regimens. BMI ≥24.0 kg/m2, HDL-C <40 and CKD increased the risks for hyperlipidemia. Among statin non-users, 33.3 % of premature-old and 40.0 % of old patients met TNHI eligibility criteria. Cardiometabolic multimorbidity is common among aging PLWH in Taiwan. The premature-old group showed considerable disease burden and treatment gaps, indicating missed prevention opportunities. These findings emphasize the need for age-appropriate, integrated care approaches to address the evolving health challenges in this population.

11 August 2025 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
BHBo-Ming Huang
Bo-Ming Huang
CLChing-Lung Lo
Ching-Lung Lo
WLWen-Liang Lin
Wen-Liang Lin
MLMing-Chi Li
Ming-Chi Li
TWTzu-Ping Weng
Tzu-Ping Weng
NLNan-Yao Lee
Nan-Yao Lee
The increasing incidence of multidrug-resistant Enterobacteriaceae (MDRE) presents a significant challenge in clinical settings. We aimed to evaluate the impact of antimicrobial stewardship interventions (ASIs) on clinical outcomes in patients with MDRE bloodstream infections (BSI). A single-center, pre-post quasi-experimental study was conducted on patients with BSIs caused by MDRE from March 1, 2014 to February 29, 2016. Infectious disease specialists actively reviewed all positive blood culture notifications and provided evidence-based recommendations for antibiotic therapy. The primary outcomes were 30-day mortality and time to appropriate antibiotics. Secondary outcomes included the hospital length of stay (LOS) after BSIs and duration of antibiotic therapy among survivors. Total 193 patients were included: 73 patients in the pre-intervention period and 120 patients in the intervention period. The 30-day mortality was lower in the intervention group (12.5% vs. 28.8%, P = 0.007). Species identification of BSI pathogens was more rapidly completed (median 70 h vs. 76 h, P = 0.001), and the time to appropriate antibiotics (median 9 h vs. 33 h, P < 0.001) and duration of antibiotic therapy (10 days vs. 12.5 days, P < 0.001) were shorter in the intervention group. Cox regression analysis revealed that ASIs were associated with a better prognosis among adults with MDRE BSIs (hazard ratio: 0.40; 95 % CI: 0.20-0.77; P = 0.006). ASIs can reduce the time to appropriate antimicrobial therapy, shorten antibiotic therapy duration, and improve clinical outcomes in patients with BSIs caused by MDRE.